Proxy Votes Now

Home › Activist investors › Sarissa Capital

Sarissa Capital

Campaign activist. Positions and campaigns from Sarissa Capital’s SEC filings. Updated November 21, 2026.

Filer entities
Sarissa Capital Management LP
SEC CIK
1577524 (Sarissa Capital Management LP)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 16, 2026: 10 US-listed positions reported; 1 of 1% or more of a company without a 13D are listed below.
3current positions
1new or changed in 90 days
0active campaigns
3campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (3)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
Amarin Corporation PLC/UK 6.1%25,743,900 shares Schedule 13D/A, filed Aug 27, 2026 Sep 5, 2023 Decreased Aug 27, 2026 ▼ 1.99 pts Decreased Standard Item 4 language
Ironwood Pharmaceuticals Inc 5.8%9,444,944 shares Schedule 13D/A, filed Mar 19, 2026 Mar 19, 2026 — — — Standard Item 4 language
Innoviva, Inc. 2.66%1,890,604 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 Nov 14, 2016 — ▲ 0.04 pts — 13F: none stated

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Amarin Corporation PLC/UK · Standard Item 4 language

“On March 25, 2025, Mr. Mark DiPaolo, a member of Issuer's board of directors (the "Board"), notified the Issuer that he does not intend to stand for reelection to the Board at the Issuer's 2025 Annual Meeting of Shareholders.”

Item 4 in the Schedule 13D/A filed Aug 27, 2026; this amendment did not restate Item 4, so the text is from the filing of Mar 25, 2025.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (3)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Innoviva, Inc.Board seats Stake reported below 5% Mar 17, 2025 Mar 13, 2017 Proxy contest filed latest (25) —
Alkermes plc.Board seats Stake reported below 5% Aug 24, 2023 May 10, 2021 Proxy contest filed latest (15) —
Amarin Corporation PLC/UKBoard seats Meeting held; result not captured Feb 28, 2023 Jan 24, 2022 Proxy contest filed latest (22) —
Past positions (2)
CompanyLast stakeSourceOutcomeDate
Sarissa Capital Management LP — Schedule 13D/A, filed Jun 12, 2023stake not read from this filing’s format: see the filing Not in the 13F for the quarter ended Dec 31, 2023 Feb 14, 2024
Alkermes plc. 5.0% Schedule 13D/A, filed Aug 24, 2023 Reported below 5% in a 13D/A Aug 24, 2023

How large managers voted in Sarissa Capital’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

No proxy contest has gone to a vote since July 1, 2023.

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

2Stake reported below 5%
1No outcome in the filings read
Outcome of each campaign (3)
CompanyOutcomeDetailDateFirst filing
Innoviva, Inc. Stake reported below 5% filing Mar 17, 2025 Mar 13, 2017
Alkermes plc. Stake reported below 5% filing Aug 24, 2023 May 10, 2021
Amarin Corporation PLC/UK No outcome in the filings read — Feb 28, 2023 Jan 24, 2022

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 1 of 4 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

CompanyFirst 13DTo latest closeSPY same dates6 months after12 months after
Ironwood Pharmaceuticals Inc IRWD Mar 19, 2026 +45.8%Mar 19, 2026 – Nov 19, 2026 +8.5% +35.0%SPY +15.4% not yet / no price

Prices: daily closes (Nasdaq), as stored by the site.

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Sarissa Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Ironwood Pharmaceuticals Inc · Sarissa Capital first disclosed Mar 19, 2026 · 6 other filings
HolderFormDateStake
Barclays PLC Schedule 13G Nov 12, 2025 1.9%
Bank of America Corp /De/ Schedule 13G Nov 14, 2025 7.4%
Armistice Capital, LLC Schedule 13G Feb 17, 2026 9.8%
Renaissance Technologies LLC Schedule 13G May 14, 2026 4.9%
BlackRock, Inc. Schedule 13G Jul 28, 2026 8.1%
State Street Corporation Schedule 13G Aug 7, 2026 5.4%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.